

CLAIMS

1. Use of an anti-CD38 antibody comprising (a) a heavy chain variable domain (V_H) that comprises: a CDR-H1 comprising the amino acid sequence DYWMQ (SEQ ID NO: 1), a CDR-H2 comprising the amino acid sequence TIYPGDGDTGYAQKFQG (SEQ ID NO: 2), and a CDR-H3 comprising the amino acid sequence GDYYGSNSLDY (SEQ ID NO: 3), and (b) a light chain variable domain (V_L) that comprises: a CDR-L1 comprising the amino acid sequence KASQDVSTVVA (SEQ ID NO: 4), a CDR-L2 comprising the amino acid sequence SASYRYI (SEQ ID NO: 5), and a CDR-L3 comprising the amino acid sequence QQHYSPPYT (SEQ ID NO: 6) in the manufacture of a medicament for treating multiple myeloma in an individual, wherein the treatment comprises the anti-CD38 antibody, carfilzomib, and dexamethasone to be administered to the individual,

wherein the anti-CD38 antibody is to be administered at a dose of 10 mg/kg, the carfilzomib is to be administered at a dose of 20 mg/m² or 56 mg/m², and the dexamethasone is to be administered at a dose of 20 mg,

wherein the individual received at least one prior therapy for multiple myeloma, and

wherein the individual is more likely to be Minimal Residual Disease negative at a threshold of 10⁻⁵ or less after treatment, as compared to a treatment with an effective amount of the carfilzomib and an effective amount of the dexamethasone without the anti-CD38 antibody.

2. Use of an anti-CD38 antibody comprising (a) a heavy chain variable domain (V_H) that comprises: a CDR-H1 comprising the amino acid sequence DYWMQ (SEQ ID NO: 1), a CDR-H2 comprising the amino acid sequence TIYPGDGDTGYAQKFQG (SEQ ID NO: 2), and a CDR-H3 comprising the amino acid sequence GDYYGSNSLDY (SEQ ID NO: 3), and (b) a light chain variable domain (V_L) that comprises: a CDR-L1 comprising the amino acid sequence KASQDVSTVVA (SEQ ID NO: 4), a CDR-L2 comprising the amino acid sequence SASYRYI (SEQ ID NO: 5), and a CDR-L3 comprising the amino acid sequence QQHYSPPYT (SEQ ID NO: 6) in the manufacture of a medicament for treating multiple myeloma in an individual, wherein the treatment comprises the anti-CD38 antibody, carfilzomib and dexamethasone to be administered to the individual,

wherein the anti-CD38 antibody is to be administered at a dose of 10 mg/kg, the carfilzomib is to be administered at a dose of 20 mg/m² or 56 mg/m², and the dexamethasone is to be administered at a dose of 20 mg,

wherein the individual received at least one prior therapy for multiple myeloma,

wherein the individual has renal impairment at the start of treatment, and

wherein the treatment improves renal impairment.

3. The use according to claim 1 or 2, wherein the treatment extends progression free survival (PFS) and/or overall survival (OS) of the individual.
4. The use according to any one of claims 1-3, wherein the individual received 1-3 prior therapies for multiple myeloma.
5. The use according to any one of claims 1-4, wherein the individual received more than three prior therapies for multiple myeloma.
6. The use according to any one of claims 1-5, wherein the individual received prior therapy with a proteasome inhibitor.
7. The use according to any one of claims 1-6, wherein the individual received prior therapy with an immunomodulatory agent.
8. The use according to any one of claims 1-7, wherein the individual is classified as Stage I or Stage II according to the Revised International Staging System for multiple myeloma (R-ISS) at the start of treatment.
9. The use according to any one of claims 1-7, wherein the individual is classified as Stage III according to R-ISS at the start of treatment.
10. The use according to any one of claims 1-7, wherein the individual is not classified according to R-ISS at the start of treatment.
11. The use according to any one of claims 1-10, wherein the individual has one or more cytogenetic abnormalities selected from the group consisting of: del(17p), t(4;14), t(14;16), and gain(1q21).
12. The use according to claim 1, wherein the individual has renal impairment at the start of treatment.
13. The use according to any one of claims 1-12, wherein the individual is 65 to less than 75 years of age at the start of the treatment.
14. The use according to any one of claims 1-13, wherein the individual is 75 years of age or older at the start of the treatment.

15. The use according to any one of claims 1-14, wherein the anti-CD38 antibody comprises a heavy chain variable region (V_H) comprising an amino acid sequence of SEQ ID NO: 7 and a light chain variable region (V_L) comprising an amino acid sequence of SEQ ID NO: 8 or SEQ ID NO: 9.
16. The use according to any one of claims 1-15, wherein the anti-CD38 antibody is isatuximab.
17. The use according to any one of claims 1-16, wherein the anti-CD38 antibody, the carfilzomib, and the dexamethasone are to be administered in a first 28-day cycle,
wherein, the anti-CD38 antibody is to be administered at the dose of 10 mg/kg on Days 1, 8, 15, and 22 of the first 28-day cycle, the carfilzomib is to be administered at the dose of 20 mg/m² on Days 1 and 2 and at a dose of 56 mg/m² on Days 8, 9, 15, and 16 of the first 28-day cycle, and the dexamethasone is to be administered at the dose 20 mg on Days 1, 2, 8, 9, 15, 16, 22, and 23 of the first 28-day cycle.
18. The use according to claim 17, wherein the anti-CD38 antibody, the carfilzomib, and the dexamethasone are to be further administered in one or more 28-day cycles following the first 28-day cycle,
wherein the anti-CD38 antibody is to be administered at the dose of 10 mg/kg on Days 1 and 15 of the one or more 28-day cycles following the first 28-day cycle, the carfilzomib is to be administered at a dose of 56 mg/m² on each of Days 1, 2, 8, 9, 15, and 16 of the one or more 28-day cycles following the first 28-day cycle, and the dexamethasone is to be administered at the dose 20 mg on Days 1, 2, 8, 9, 15, 16, 22, and 23 of the one or more 28-day cycles following the first 28-day cycle.
19. The use according to any one of claims 1 or 18, wherein the individual is MRD negative at a threshold of 10^{-5} or less after the treatment.